Loading...
OTCM
ERBKY
Market cap10mUSD
Jul 27, Last price  
12.04USD
Name

Creso Pharma Ltd

Chart & performance

D1W1MN
OTCM:ERBKY chart
P/E
P/S
EPS
Div yield, %
Shrs. gr., 5y
4.37%
Rev. gr., 5y
100.90%
Revenues
19m
+117.76%
020,92508,022243,798578,2223,626,4272,447,7616,218,3378,689,00018,921,000
Net income
-52m
L+59.98%
0-9,953-138,864-4,584,239-15,076,076-16,756,036-17,053,384-37,577,192-31,765,746-32,782,000-52,446,000
CFO
0
P
000-1,857,414-5,895,937-8,173,313-10,166,956-9,621,580-22,377,916-30,833,0000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Creso Pharma Limited is a global pharmaceutical company focused on the development, registration, and commercialization of advanced cannabis and hemp-based solutions. These therapeutic products and nutraceuticals are designed for both human and animal health applications, with market presence spanning Europe, the Middle East, North America, and the Asia Pacific region. Beyond innovative product creation, the company also manages the cultivation, processing, and distribution of cannabis products, extending its reach to the retail sector. Its diverse portfolio includes specialized offerings such as anibidiol, a complementary nutritional supplement for companion animals. For human wellness, they provide cannaQIX, a nutraceutical blend of hemp oil extract, vitamins, and zinc, formulated to alleviate stress and bolster psychological and neurological functions. The company also manufactures topical and dermatological products, including cannaDOL, a CBD-infused gel combining cooling and warming essential oils. Established in 2015, Creso Pharma Limited maintains its headquarters in Nedlands, Australia.
IPO date
Oct 20, 2016
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT